国产一区二区三区国产精品,少妇爆乳中文字幕

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專(zhuān)享價(jià)	數(shù)量
5 mg	3-5days	￥450.00	登錄后可見(jiàn)	- +
10 mg	3-5days	￥650.00	登錄后可見(jiàn)	- +
25 mg	3-5days	￥950.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專(zhuān)享價(jià)

數(shù)量

5 mg

3-5days

￥450.00

登錄后可見(jiàn)

- +

10 mg

3-5days

￥650.00

登錄后可見(jiàn)

- +

25 mg

3-5days

￥950.00

登錄后可見(jiàn)

- +

基本信息

英文名稱(chēng)	Quizartinib (AC220)
中文名稱(chēng)	奎扎替尼
CAS號(hào)	950769-58-1
分子式	C29H32N6O4S
分子量	560.67
外觀	White to off-white powder
儲(chǔ)存條件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

產(chǎn)品詳情

Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.

相關(guān)文獻(xiàn)

抱歉，暫時(shí)沒(méi)有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄

CL2519

奎扎替尼

950769-58-1 98+% 3-5days

￥450.00 5 mg

中国女人和老外的毛片_少妇激情作爱视频_成人无码区免费AⅤ片在线观看_国产freeXXXX性播放_欧美人与性囗牲恔配的起源

奎扎替尼

Quizartinib (AC220)

化學(xué)品安全說(shuō)明書(shū)(MSDS)